Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term nf-kappa-b. Found 15 abstracts

Ralff MD, El-Deiry WS. TRAIL pathway targeting therapeutics. Expert Rev Precis Me. 2018 May;3(3):197-204.   PMCID: PMC6366666
Rao SY, Lee SY, Gutierrez A, Perrigoue J, Thapa RJ, Tu ZG, Jeffers JR, Rhodes M, Anderson S, Oravecz T, Hunger SP, Timakhov RA, Zhang RG, Balachandran S, Zambetti GP, Testa JR, Look AT, Wiest DL. Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. Blood. 2012 Nov;120(18):3764-73.   PMCID: PMC3488889
Irrinki KM, Mallilankaraman K, Thapa RJ, Chandramoorthy HC, Smith FJ, Jog NR, Gandhirajan RK, Kelsen SG, Houser SR, May MJ, Balachandran S, Madesh M. Requirement of FADD, NEMO, and BAX/BAK for Aberrant Mitochondrial Function in Tumor Necrosis Factor Alpha-Induced Necrosis. Molecular and Cellular Biology. 2011 Sep;31(18):3745-58.   PMCID: PMC3165716
Al-Katib A, Arnold AA, Aboukameel A, Sosin A, Smith P, Mohamed AN, Beck FW, Mohammad RM. I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma - art. no. 228. Molecular Cancer. 2010 Sep;9:228.   PMCID: PMC2940845
Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 2009 Nov;115(2):215-20.
Stein R, Smith MR, Chen S, Zalath M, Goldenberg DM. Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines. Clinical Cancer Research. 2009 Apr;15(8):2808-17.   PMCID: PMC 2681251
Nam JS, Kang MJ, Suchar AM, Shimamura T, Kohn EA, Michalowska AM, Jordan VC, Hirohashi S, Wakefield LM. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. CANCER RESEARCH. 2006 Jul;66(14):7176-84.
Yuan ZQ, Kim D, Kaneko S, Sussman M, Bokoch GM, Kruh GD, Nicosia SV, Testa JR, Cheng JQ. ArgBP2 gamma interacts with akt and p21 activated kinase-1 and promotes cell survival. Journal of Biological Chemistry. 2005 Jun 03;280(22):21483-90.
Adler V, Yin ZM, Tew KD, Ronai Z. Role of redox potential and reactive oxygen species in stress signaling. Oncogene. 1999 Nov;18(45):6104-11.
Gate L, Paul J, Ba GN, Tew KD, Tapiero H. Oxidative stress induced in pathologies: the role of antioxidants. Biomedicine & Pharmacotherapy. 1999 May;53(4):169-80.
Law SF, Zhang YZ, Fashena SJ, Toby G, Estojak J, Golemis EA. Dimerization of the docking/adaptor protein HEF1 via a carboxy- terminal helix-loop-helix domain. Experimental Cell Research. 1999 Oct 10;252(1):224-35.
Wu GS, Burns TF, McDonald ER, Meng RD, Kao G, Muschel R, Yen T, El-Deiry WS. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest. Oncogene. 1999 Nov 11;18(47):6411-8.
Tumang JR, Owyang A, Andjelic S, Jin Z, Hardy RR, Liou ML, Liou HC. c-Rel is essential for B lymphocyte survival and cell cycle progression. European Journal of Immunology. 1998 Dec;28(12):4299-312.
Jaiswal AK, Venugopal R, Mucha J, Carothers AM, Grunberger D. Caffeic acid phenethyl ester stimulates human antioxidant response element-mediated expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene. Cancer Research. 1997 Feb;57(3):440-6.
Maki A, Mohammad RM, Smith M, AlKatib A. Role of ubiquitin carboxyl terminal hydrolase in the differentiation of human acute lymphoblastic leukemia cell line, Reh. Differentiation. 1996 Mar;60(1):59-66.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term nf-kappa-b

nf-kappa-b apoptosis expression p53 gene-expression bcl-2 gene protein homology domain bortezomib rel activated protein-kinases Id2 human b- family-members molecular-cloning gastric epithelial-cells acute lymphoblastic-leukemia proliferation reactive oxygen ATM targeted disruption conserved cysteine oxidative stress activation helix-loop-helix (HLH) combination therapy human t-lymphocytes controlling cells in-vivo ataxia-telangiectasia terminal kinase refractory multiple-myeloma yeast induced apoptosis multiple-myeloma cells chemotherapeutic-agents in-vitro therapy adhesion system vitamin-e t-cell development glutathione-s-transferase cytochrome-c release receptor mice lacking necrotic cell-death pseudohyphae saccharomyces-cerevisiae progression adapter protein KILLER NF- Proteosome inhibition antitumor-activity ya subunit gene dimerization residues survival link na+ diseases cell-death free radicals G1 arrest small-molecule onc201 heat-shock b nitric-oxide interacting HEF1 cd40 k+-atpase small-molecule inhibitor follicular lymphoma kappa B GST TRAIL monocyte chemoattractant protein-1 transcription factors phosphatidylinositol 3-kinase cd74 invivo translational control signal-transduction hiv-1 replication cancer ligand trail lipid-peroxidation jun ap-1 focal adhesion kinase antigen receptor dna-damage ionizing-radiation interleukin-8 production transformed phenotype antioxidants mediated cell-adhesion family proteasome inhibitor stress kinases e-cadherin low-density-lipoprotein tyrosine-phosphorylation mediated apoptosis cell-cycle checkpoint bax gene death receptor dr4 lipoic acid chain apoptosis-inducing ligand human cancer-cells advanced solid tumors synthase cyclophilin-d docking protein signaling pathways cytotoxic superoxide-dismutase gene phenolic antioxidants rnase-h alpha- Oncology cytochrome-c clinical-significance inhibition pegylated liposomal doxorubicin substrate-related protein p-glycoprotein pgp 95 estrogen-receptor cancer-therapy resistance serine-threonine kinase Ovarian cancer thioredoxin tic10 DR5 growth suppression large-cell lymphoma induced tumor promotion ROS NF-kappa B monoclonal-antibody lymphoma transformed-cells kinase-beta inhibitor Bortezomib nitric-oxide modification oxygen radicals
Last updated on Wednesday, February 05, 2020